Novo Nordisk Licenses Nanexa Drug Tech in Deal Worth Up to €1.17 Billion

3-line summary

• Novo Nordisk licensed Nanexa's drug technology in a deal worth up to €1.17 billion, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.